Australia's largest stock trading and investment forum Australia's #1 stock forum

ODA

2.70%

18.0¢ orcoda limited

[INTERVIEW] ODA Managing Director discusses robust growth in Q3 Report, page-8

First 8 Last

Share
Profile

Follow
Davisite

19,326 Posts.

6430

09/05/23

13:22

Post #: 67678654
Share

Originally posted by Pooslice ↑

based on what exactly? the company currently has a profit of $1m a year (which is very good), and is now valued at $40m+

if someone tried to sell me a business for $40m when it was making $1m profit.... (and yeah yeah I know people are going to bring up other, even worse companies, but comparing myself to hitler doesn't make me a good person).

I'm optimistic for the future of this company but I think this little surge recently has more to do with a few very keen buyers, than it is a reflection of broader market sentiment.

if I was a betting man, and I'm on the asx so clearly I am, I'd say that some of the recent cap raise participants will start finding the 100%+ gain a little too tempting to pass

all imo. not advice. dyor.

Expand

ODA is making more than $1m a quarter in free cashflow - this is $4m a year.

ODA Price at posting: 25.5¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

BUX

Buxton projects new graphite province discovery at WA Narryer play

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

First 8 Last

Add ODA (ASX) to my watchlist

(20min delay)
Last 18.0¢		Change -0.005(2.70%)		Mkt cap ! $30.44M

Open	High	Low	Value	Volume
18.0¢	18.0¢	18.0¢	$1	3

Buyers (Bids)

No.	Vol.	Price($)
1	32500	14.5¢

Sellers (Offers)

Price($)	Vol.	No.
17.5¢	3	1

View Market Depth

No.	Vol.	Price($)
1	32500	0.145
1	30000	0.140
1	2000	0.130
1	60000	0.050
0	0	0.000

Price($)	Vol.	No.
0.175	3	1
0.180	95997	1
0.195	2330	1
0.200	66618	3
0.210	50000	1

Last trade - 11.14am 04/10/2024 (20 minute delay)

ODA (ASX) Chart

[INTERVIEW] ODA Managing Director discusses robust growth in Q3 Report, page-8

Buxton projects new graphite province discovery at WA Narryer play

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

BCI reaches close of funding facility for salt-first part of Mardie project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

[INTERVIEW] ODA Managing Director discusses robust growth in Q3 Report, page-8

Top Stories

Buxton projects new graphite province discovery at WA Narryer play

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

BCI reaches close of funding facility for salt-first part of Mardie project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News